Li-Fraumeni syndrome

Overview

Li-Fraumeni syndrome (LFS) is a rare genetic condition that significantly increases the likelihood of developing multiple types of cancer. It is considered a hereditary cancer predisposition syndrome, meaning the increased risk runs in families. Individuals with LFS often develop cancers at younger ages than typically observed in the general population, and they may experience multiple primary tumours over their lifetime.

While LFS is rare, its impact on affected families can be substantial due to the high cancer burden. Understanding the syndrome is crucial for appropriate screening and management strategies, which aim to detect cancers early or reduce their risk.

Symptoms & clinical features

Li-Fraumeni syndrome does not have specific symptoms in itself, but rather it is defined by the development of particular types of cancer across multiple organ systems. The range of cancers associated with LFS is broad. Common cancers include soft tissue sarcomas affecting connective tissues such as muscle or fat, osteosarcomas affecting bone, pre-menopausal breast cancer, brain tumours, adrenocortical carcinomas affecting the adrenal glands, and leukaemia.

Other less common cancers can also be associated with LFS. The specific types of cancer, their age of onset, and their severity can vary significantly even within the same family. Often, the first sign of LFS in a family is a pattern of early-onset cancers affecting multiple family members.

Video: Is cancer in your genes?

Affected organs

Li-Fraumeni syndrome can affect a wide range of organs and body systems due to its predisposition to various cancer types. The most commonly affected systems include bones, where osteosarcomas may arise, soft tissues that can develop sarcomas, the brain which may be affected by tumours, the breast where cancer may occur, and the adrenal glands which may develop adrenocortical carcinoma. The blood-forming cells can also be affected, leading to leukaemia.

Given the diverse nature of LFS-associated cancers, virtually any organ or tissue in the body could potentially develop a tumour, though the aforementioned sites are the most frequently observed. The critical role of TP53 in suppressing tumour formation means its dysfunction can have widespread effects.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Individuals with Li-Fraumeni syndrome face a substantially elevated lifetime risk of developing cancer. Cancers often develop at younger ages than typically seen in the general population. Females with LFS have a particularly high risk of early-onset breast cancer.

The severity of LFS is directly related to the high cancer risk and the potential for multiple primary tumours throughout life. The specific risks and severity can depend on the exact genetic change in TP53 and other modifying factors, though these are not fully understood. Early diagnosis and intensive surveillance are crucial for managing these risks and potentially improving outcomes.

Genetic causes

Li-Fraumeni syndrome is primarily caused by inherited pathogenic variants in TP53. This gene provides instructions for making the p53 protein, a molecule that determines the cellular response when DNA becomes damaged - either triggering repair mechanisms or initiating cell death. Pathogenic variants in TP53 impair this surveillance function, reducing the protein's ability to manage cells carrying genetic damage. As a result, cells with damaged DNA may continue dividing rather than being eliminated, potentially leading to tumour formation. This compromised cellular oversight explains the markedly elevated cancer risk characteristic of Li-Fraumeni syndrome.

• TP53
  tumor protein p53
  TP53 encodes tumour protein p53, a critical regulator of cell division and DNA repair often called the guardian of the genome.

Inheritance pattern

Li-Fraumeni syndrome follows an autosomal dominant inheritance pattern. This means that a person only needs to inherit one copy of the altered TP53 gene from one parent to be affected by the condition. If a parent has LFS, there is a 50% chance with each pregnancy that their child will inherit the pathogenic TP53 variant and therefore also have LFS.

LFS can also arise from a de novo (new) pathogenic variant, meaning the genetic change occurs for the first time in an individual and was not inherited from either parent. In such cases, the affected individual would be the first in their family to have the condition, but they could then pass it on to their children. Family members of an affected individual may be offered genetic counselling and testing to determine their own risk.

Diagnosis & testing

The diagnosis of Li-Fraumeni syndrome is typically suspected based on a family history of specific cancers at young ages or the occurrence of multiple primary cancers in an individual. Clinical diagnostic criteria, such as the Chompret criteria or classic Li-Fraumeni syndrome criteria, are often used to identify individuals who should be offered genetic testing.

Confirmation of LFS is achieved through molecular genetic testing, which looks for pathogenic variants in TP53. In the UK, individuals are usually referred to a clinical genetics service by their GP or another specialist to discuss the possibility of genetic testing. This testing falls under the NHS Genomic Medicine Service and would typically be requested using an appropriate NHS test code. Genetic counselling is an integral part of this process, providing information and support before and after testing.

Management & lifestyle

Managing Li-Fraumeni syndrome primarily focuses on early cancer detection through intensive surveillance and, where appropriate, risk-reducing interventions. There is a general consensus that individuals with LFS should participate in a comprehensive, lifelong cancer screening programme. This may include regular physical examinations, blood tests, and imaging studies, such as whole-body MRI scans, along with other investigations depending on individual risk factors and guidelines.

In some cases, risk-reducing surgery, such as prophylactic mastectomy, may be considered, particularly for women with a very high risk of breast cancer. Some clinicians may advise limiting exposure to known carcinogens like excessive sun exposure and tobacco smoke. All management decisions are made in consultation with a multidisciplinary team, including clinical geneticists, oncologists, and other specialists, within the framework of the NHS Genomic Medicine Service. Genetic counsellors play a vital role in helping individuals and families understand and navigate these complex management pathways.

UK care pathway

In the UK, individuals suspected of having Li-Fraumeni syndrome are typically referred to a specialist clinical genetics service. This referral can come from a GP, an oncologist, or another consultant. The clinical genetics team will assess family history and clinical features, offering genetic counselling and, if appropriate, genetic testing through the NHS Genomic Medicine Service.

Genetic testing for Li-Fraumeni syndrome is typically performed under specific NHS R-codes. Following a diagnosis, individuals are generally offered a comprehensive surveillance programme, often managed through specialist clinics. Genetic counsellors provide ongoing support, helping patients and their families understand the implications of the diagnosis and available management strategies.

Related conditions

When considering Li-Fraumeni syndrome, it is helpful to be aware of other hereditary cancer predisposition syndromes. While LFS is characterised by a broad spectrum of cancers, other syndromes may have a more focused cancer risk. For instance, some hereditary cancer syndromes primarily increase the risk of breast and ovarian cancers, while others are predominantly associated with colorectal and endometrial cancers.

Although there can be some overlap in cancer types, the overall spectrum and the specific genetic causes help to distinguish these conditions. Accurate genetic testing is key to establishing the correct diagnosis and guiding appropriate management.

• Somatic TP53 mosaicism
  Cancer Predisposition
  Shares 1 gene

Frequently asked questions

References

1. Gargallo P, Yáñez Y, Segura V. Li-Fraumeni syndrome heterogeneity. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020. PMID: 31691207
2. Correa H. Li-Fraumeni Syndrome. Journal of pediatric genetics. 2016. PMID: 27617148
3. Vogel WH. Li-Fraumeni Syndrome. Journal of the advanced practitioner in oncology. 2017. PMID: 30333936
4. Swaminathan M, Bannon SA, Routbort M. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harbor molecular case studies. 2019. PMID: 30709875
5. Chamarthi VS, Kasi A. Li-Fraumeni Syndrome. 2026. PMID: 30335319
6. Ossa CA, Molina G, Cock-Rada AM. Li-Fraumeni syndrome. Biomedica : revista del Instituto Nacional de Salud. 2016. PMID: 27622479
7. Fortuno C, Frone MN, Mester J. A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome. Genome medicine. 2025. PMID: 41126324
8. Malkin D. Li-fraumeni syndrome. Genes & cancer. 2011. PMID: 21779515